142 related articles for article (PubMed ID: 33887302)
1. Expression of uroplakin II and GATA-3 in bladder cancer mimickers: caveats in the use of a limited panel to determine cell of origin in bladder lesions.
Leivo MZ; Tacha DE; Hansel DE
Hum Pathol; 2021 Jul; 113():28-33. PubMed ID: 33887302
[TBL] [Abstract][Full Text] [Related]
2. Utility of uroplakin II expression as a marker of urothelial carcinoma.
Tian W; Guner G; Miyamoto H; Cimino-Mathews A; Gonzalez-Roibon N; Argani P; Li X; Sharma R; Subhawong AP; Rezaei K; Bivalacqua TJ; Epstein JI; Bishop JA; Netto GJ
Hum Pathol; 2015 Jan; 46(1):58-64. PubMed ID: 25449628
[TBL] [Abstract][Full Text] [Related]
3. A combination of p40, GATA-3 and uroplakin II shows utility in the diagnosis and prognosis of muscle-invasive urothelial carcinoma.
Leivo MZ; Elson PJ; Tacha DE; Delahunt B; Hansel DE
Pathology; 2016 Oct; 48(6):543-9. PubMed ID: 27594510
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical Differentiation of Plasmacytoid Urothelial Carcinoma From Secondary Carcinoma Involvement of the Bladder.
Borhan WM; Cimino-Mathews AM; Montgomery EA; Epstein JI
Am J Surg Pathol; 2017 Nov; 41(11):1570-1575. PubMed ID: 28786878
[TBL] [Abstract][Full Text] [Related]
5. Uroplakin II is a more sensitive immunohistochemical marker than uroplakin III in urothelial carcinoma and its variants.
Li W; Liang Y; Deavers MT; Kamat AM; Matin SF; Dinney CP; Czerniak B; Guo CC
Am J Clin Pathol; 2014 Dec; 142(6):864-71. PubMed ID: 25389341
[TBL] [Abstract][Full Text] [Related]
6. Uroplakin II (UPII), GATA3, and p40 are Highly Sensitive Markers for the Differential Diagnosis of Invasive Urothelial Carcinoma.
Hoang LL; Tacha D; Bremer RE; Haas TS; Cheng L
Appl Immunohistochem Mol Morphol; 2015; 23(10):711-6. PubMed ID: 25611245
[TBL] [Abstract][Full Text] [Related]
7. Uroplakin II as a single marker for luminal versus basal molecular subtypes in muscle invasive urothelial carcinoma.
Pryma C; Villamil C; Gibb EA; Oo HZ; Seiler R; Contreras-Sanz A; Douglas J; Black PC; Wang G
Virchows Arch; 2022 Sep; 481(3):397-403. PubMed ID: 35612672
[TBL] [Abstract][Full Text] [Related]
8. PAX8 positivity in nested variant of urothelial carcinoma: a potential diagnostic pitfall.
Legesse T; Matoso A; Epstein JI
Hum Pathol; 2019 Dec; 94():11-15. PubMed ID: 31669177
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemistry in diagnostic surgical pathology of the prostate.
Hameed O; Humphrey PA
Semin Diagn Pathol; 2005 Feb; 22(1):88-104. PubMed ID: 16512601
[TBL] [Abstract][Full Text] [Related]
10. Distinct Uroplakin II Staining Pattern in Apocrine Breast Carcinoma.
van Pel DM; Pors J; Yuen E; Chan R; Kos Z; Hayes MM; Wang G
Appl Immunohistochem Mol Morphol; 2022 Nov-Dec 01; 30(10):681-686. PubMed ID: 36227121
[TBL] [Abstract][Full Text] [Related]
11. Detection of circulating uroplakin-positive cells in patients with transitional cell carcinoma of the bladder.
Li SM; Zhang ZT; Chan S; McLenan O; Dixon C; Taneja S; Lepor H; Sun TT; Wu XR
J Urol; 1999 Sep; 162(3 Pt 1):931-5. PubMed ID: 10458411
[TBL] [Abstract][Full Text] [Related]
12. Nephrogenic adenoma of the urinary tract: A 6-year single center experience.
Turcan D; Acikalin MF; Yilmaz E; Canaz F; Arik D
Pathol Res Pract; 2017 Jul; 213(7):831-835. PubMed ID: 28554748
[TBL] [Abstract][Full Text] [Related]
13. Expression and localization of four uroplakins in urothelial preneoplastic lesions.
Zupančič D; Zakrajšek M; Zhou G; Romih R
Histochem Cell Biol; 2011 Oct; 136(4):491-500. PubMed ID: 21853341
[TBL] [Abstract][Full Text] [Related]
14. Potential utility of uroplakin III, thrombomodulin, high molecular weight cytokeratin, and cytokeratin 20 in noninvasive, invasive, and metastatic urothelial (transitional cell) carcinomas.
Parker DC; Folpe AL; Bell J; Oliva E; Young RH; Cohen C; Amin MB
Am J Surg Pathol; 2003 Jan; 27(1):1-10. PubMed ID: 12502922
[TBL] [Abstract][Full Text] [Related]
15. A newly developed uroplakin II antibody with increased sensitivity in urothelial carcinoma of the bladder.
Hoang LL; Tacha DE; Qi W; Yu C; Bremer RE; Chu J; Haas TS; Cheng L
Arch Pathol Lab Med; 2014 Jul; 138(7):943-9. PubMed ID: 24978921
[TBL] [Abstract][Full Text] [Related]
16. Detection of circulating cancer cells expressing uroplakins and epidermal growth factor receptor in bladder cancer patients.
Osman I; Kang M; Lee A; Deng FM; Polsky D; Mikhail M; Chang C; David DA; Mitra N; Wu XR; Sun TT; Bajorin DF
Int J Cancer; 2004 Oct; 111(6):934-9. PubMed ID: 15300806
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Antibodies to Detect Uroplakin in Urothelial Carcinomas.
Kristoffersen HL; Røge R; Nielsen S
Appl Immunohistochem Mol Morphol; 2022 May-Jun 01; 30(5):326-332. PubMed ID: 35510771
[TBL] [Abstract][Full Text] [Related]
18. Prospective evaluation of the prognostic relevance of molecular staging for urothelial carcinoma.
Copp HL; Chin JL; Conaway M; Theodorescu D
Cancer; 2006 Jul; 107(1):60-6. PubMed ID: 16691580
[TBL] [Abstract][Full Text] [Related]
19. Serous Carcinoma Mimicking Primary Urothelial Carcinoma on Clinical Evaluation and Pathology: A Potential Diagnostic Pitfall.
Mirsadraei L; Hodkoff A; Jones K; Shabaik A; Kader AK; Saenz CC; Montironi R; Tacha DE; Fadare O; Hansel DE
Arch Pathol Lab Med; 2018 Feb; 142(2):168-177. PubMed ID: 28795841
[TBL] [Abstract][Full Text] [Related]
20. The applicability and utility of immunohistochemical biomarkers in bladder pathology.
Akgul M; MacLennan GT; Cheng L
Hum Pathol; 2020 Apr; 98():32-55. PubMed ID: 32035992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
